AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$INDV

Heidbreder Christian sold $765K of INDV

Heidbreder Christian (Chief Scientific Officer) sold 18,586 shares of Indivior Pharmaceuticals, Inc. (INDV) at $41.14 ($0.76M total) on 2026-07-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Heidbreder Christian
Published Jul 13, 2026, 8:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 13, 2026, 8:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$INDV
Neutral
medium confidence
Mentioned
$INDV
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INDVNeutralLow
01

Why it matters

The disclosure updates the insider activity record and may influence sentiment, but it does not provide new operational, clinical, or financial information about Indivior.

02

Market read

Traders may monitor for patterns in subsequent insider filings, but this specific transaction is likely routine given the 10b5-1 plan.

03

What to watch

10b5-1 plans can produce sales regardless of company outlook; without additional context (e.g., multiple consecutive sales, option exercises, or purchases), signal quality is low.

Relevance 4/10Novelty 5/10Timing: after-hours/next-session read-through from a newly filed Form 4 (filed 2026-07-13)

Background

The filing is an SEC Form 4 insider transaction by Indivior’s Chief Scientific Officer, reported as an open-market sale under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$INDVNeutralMedium confidence
Context

Indivior CSO Christian Heidbreder sold 18,586 shares on 2026-07-10 for about $764,628 under a 10b5-1 plan.

Expected impact

Likely limited, short-lived impact unless follow-on filings show unusual acceleration or size.

Evidence & confidence

Form 4 shows an open-market sale by an officer with a pre-arranged 10b5-1 plan; such sales are typically less informative than unscheduled transactions.

Market effects

Sector

Minimal; insider selling by a single pharma executive rarely changes sector risk materially.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

A large officer sale can still be interpreted as confidence in liquidity needs or portfolio rebalancing, but traders may overreact despite the 10b5-1 structure.

Key entities

  • issuer
    Indivior Pharmaceuticals, Inc.

    Subject of the Form 4 insider sale disclosure (INDV).

  • insider
    Heidbreder Christian

    Chief Scientific Officer who sold 18,586 shares on 2026-07-10.

  • trading mechanism
    10b5-1 plan

    Pre-arranged plan indicating the sale schedule was set in advance.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

INDV insider trading history →

Related articles

$SUPNMed

Supernus undervalued after Indivior merger, says Bank of America

Bank of America initiated coverage of Supernus Pharmaceuticals (SUPN) with a 'buy' rating and $47 price target, citing its merger with Indivior. The combined entity is expected to have a broader portfolio and stronger earnings potential. Bank of America forecasts 6% annual revenue and EPS growth over five years, with legacy Supernus products driving two-thirds of revenue growth.

finance.yahoo.com
$SUPNHighAI 9/10

Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader

Supernus Pharmaceuticals (SUPN) and Indivior completed their merger, creating Supernus, Inc. The combined company will trade on Nasdaq under 'SUPN' starting November 3, 2026. The merger enhances financial flexibility, expands the CNS-focused portfolio, and positions the company for long-term growth. Former Indivior shareholders will receive a $1 billion cash dividend, financed by debt and existing cash.

biobuzz.io
$INDVHighAI 8/10

Why Indivior Pharmaceuticals Stock Topped the Market Today

Indivior Pharmaceuticals (NASDAQ:INDV) shares rose 3% on its last day as a standalone company after completing a merger with Supernus Pharmaceuticals (NASDAQ:SUPN). The combined company, to be named Supernus, aims for $125M in annual cost synergies, with Indivior shareholders owning 56.5% of the new entity.

finance.yahoo.com
$SUPNHighAI 8/10

Supernus Pharmaceuticals Completes Merger with Indivior Pharmaceuticals

Supernus Pharmaceuticals (SUPN) completed its merger with Indivior Pharmaceuticals on November 2, 2026, forming Supernus, Inc. The combined company has an 11-product portfolio and headquarters in Rockville, Maryland. Supernus stockholders received 1.5401 Indivior shares per Supernus share. The company borrowed $650 million to fund a $1 billion dividend to Indivior stockholders.

tipranks.com
$INDVHighAI 9/10

Indivior Pharmaceuticals, Inc. (INDV): Completion of Acquisition or Disposition of Assets

Indivior Pharmaceuticals, Inc. (INDV) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader · Merger positions Supernus as a leading diversified central nervous system (CNS) biopharmaceutical company with a broad portfolio of marketed medicines, enhanced financial flex

SEC EDGAR 8-K